Endogenex
PrivateLast Round
Series C
Extension
Mar 25, 2026
Total Funding Raised
$240.51M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Endogenex operates in Healthcare & Life Sciences and is based in Plymouth, Minnesota. Its latest recorded funding round was a Series C Extension round in March 2026.
Endogenex is a medical technology company that develops minimally invasive, endoscopic procedures using non-thermal pulsed electric fields to treat type 2 diabetes by resetting metabolic signaling in the duodenum.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endogenex Comparables
Compare Endogenex with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fractyl Health | 88% | |
| Aqua Medical | 85% | |
| Digma Medical | 85% |
For institutional investors. Book with your work email.
Endogenex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Mar 25, 2026 | ||||
| Series C | Jun 25, 2024 | ||||
| Series B Extension | Oct 11, 2023 | ||||
| Series A | Feb 21, 2023 | ||||
| Series A Extension | Apr 19, 2021 | ||||
Series A | Nov 30, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Endogenex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C Extension, Series A Extension, Series C, Series A |
| Arboretum Ventures | Series C Extension, Series C |
| Hatteras Venture Partners | Series C Extension, Series C |
| Orlando Health Ventures | Series C Extension, Series C |
| Santé Ventures | Series C Extension, Series C |
| Intuitive Ventures | Series C Extension, Series A, Series A Extension, Series C |
| Mayo Clinic Ventures | Series C Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 36% MoM, reaching 3.4K.
- Mar 25, 2026
$50M Series C Extension round completed.
For institutional investors. Book with your work email.
Endogenex Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Endogenex's valuation, stock price, and market status.
Is Endogenex a public or private company?
Endogenex is a private company.
What is the current stock price of Endogenex?
Endogenex is a private company, so its shares have no public market price. Caplight tracks Endogenex's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Endogenex worth (valuation)?
Valuation information for Endogenex is not publicly available.
Can I buy Endogenex stock?
Endogenex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Endogenex's last funding round?
Endogenex's most recent funding round was Series C Extension on March 25, 2026.
Who are the main investors in Endogenex?
Key investors in Endogenex include Longitude Capital, Arboretum Ventures, Food and Drug Administration, Santé Ventures.
Will Endogenex IPO soon?
No public IPO plans have been announced for Endogenex.
How can I track Endogenex secondary market activity?
Caplight tracks bids, offers, and trades in Endogenex's shares on secondary markets.